

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number 09/891,206
Filing Date June 26, 2001
First Named Inventor ATHERTON et al.
Group Art Unit 1616
Examiner Name Unassigned — PAK, J.
Attorney Docket Number PHARMA-131

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	8	Fernandez-GAVARRON et al., "Incorporation of 140-lanthanum into bones, teeth and hydroxyapatite", <u>Bone and Mineral</u> 3, 1998, pp. 283-291	
	9	YANAGIHARA et al., "Synthesis of Lanthanide Carbonates", <u>Journal of the Less-Common Metals</u> , 167: 1991, pp 223-232	
	10	Guggino et al., "Bone remodeling signaled by a dihydropyridine- and phenylalkylamine-sensitive calcium channel", <u>Proc. Natl. Acad. Sci.</u> , 86: April 1999, pp. 2957-2960	
	11	GRAFF et al., "A Possible Non-aluminum oral phosphate binder? A Comparative Study on Dietary Phosphorus Absorption", <u>Research Communications in Molecular Pathology and Pharmacology</u> , Sep. 1995, pp. 373-388, Vol 89, No. 3	
	12	HERGESELL et al., Phosphate binders on iron basis: A new perspective?, <u>Kidney International</u> , 1999, pp. S-42-S-45, Vol. 56., Suppl. 73	
	13	HUTCHINSON et al., "Calcitriol, Lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy", <u>Proceedings of the ISPD '98 - The VIIIth Congress of the ISPD</u> , August 28-26, 1998, pp. S408-S412	
	14	KARPINSKI et al. "A dihydropyridine-Sensitive Calcium Channel in Rodent Osteoblastic Cells", <u>Calcif. Tissue Int.</u>, 45: 1989, pp 54-57.	
	15	J. MCCLURE et al., "The production of Calcification in connective Tissue and Skeletal Muscle Using Various Chemical Compounds", <u>Calcif Tiss. Res.</u> , 22: 1976, pp.129-135	
	16	SHANKAR et al., "Activation and inactivation of the osteoclast Ca ²⁺ receptor by the trivalent cation, La ³⁺ ", <u>Biochemical and Biophysical Research Communications</u> , 187 (2): Sep. 16, 1992, pp 907-912	
	17	ZIMMERMANN et al., "Inhibition of chondrogenesis and endochondral mineralization in vitro by different calcium channel blockers", <u>European Journal of Cell Biology</u> , 1994, pp. 114-121, Vol 63	
	18	Harris et al., "The Effect of Lanthanum Chloride and related Compounds on Calcification", <u>Arch. int. Pharmacodyn.</u> , 1970, pp. 269-278, Vol. 186	
	19	DOTY et al., "Morphological Evidence of gap Junctions Between Bone Cells", <u>Calcif. Tissue Int.</u> , 1981, pp 509-512, Vol. 33	

Examiner Signature

Date Considered

1/20/03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

RECEIVED
MAY 10 2002
TECH CENTER 1600/2900

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.